CTOs on the Move

Blue Sun Biodiesel

www.gobluesun.com

 
Blue Sun Biodiesel is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.gobluesun.com
  • 14143 Denver West Cir Ste 100
    Golden, CO USA 80401
  • Phone: 303.865.7700

Executives

Name Title Contact Details

Similar Companies

Peptilogics

Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics` lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.

Biodyne Inc

Biodyne Inc is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Croda

Croda is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProteoCell Biotechnologies

ProteoCell Biotechnologies Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeekâ„¢, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.